A phase 2 study of Enterprise Therapeutics’ cystic fibrosis (CF) therapy candidate achieved its primary goal, advancing the biotech’s effort to pursue a target that several companies, including Vertex Pharmaceuticals, have previously explored.
The U.K.-based company enrolled 57 CF patients in the two-part trial. Following an initial assessment of safety and tolerability, researchers randomized participants to receive either ETD001 or a placebo to measure the impact of the inhaled ENaC inhibitor on lung function. Patients received ETD001 or placebo twice daily for 27 days, followed by a single dose on the 28th day before evaluation of the primary goal.
Enterprise reported a statistically significant 3.4 percentage-point boost in lung function, measured by ppFEV1, among patients receiving ETD001 compared with placebo, thereby meeting the study’s main endpoint. An evaluative analysis further suggested that participants taking ETD001 were three times more likely to show ppFEV1 improvement than those given a placebo.
Although the magnitude of improvement was smaller than the double-digit gains observed in studies involving CFTR modulators, Enterprise is specifically focusing on the roughly 10% of CF patients who are not eligible for those therapies. Patients who had used CFTR modulators within 60 days prior to screening were excluded from the study.
Individuals who cannot receive medicines such as Alyftrek from Vertex lack access to disease-modifying treatments, which contributes to worsening lung function and poorer outcomes compared with patients treated using CFTR modulators. Drug developers have long viewed ENaC inhibitors as a potential option for patients without the mutations required for CFTR modulation. However, enthusiasm surrounding the field diminished after an active period roughly a decade ago.
Vertex paid Parion Sciences $80 million upfront in 2015 for rights to ENaC inhibitors before discontinuing the programs five years later. In 2023, Parion disclosed plans to launch a phase 3 study in primary ciliary dyskinesia, though the biotech has not issued a press release since that announcement. During its collaboration with Vertex, Parion also conducted phase 2 studies of the therapy for cystic fibrosis.
Boehringer Ingelheim also advanced an ENaC inhibitor into phase 2 testing. However, the company later halted development after the midstage cystic fibrosis study failed to demonstrate sufficient evidence of clinical benefit. AstraZeneca similarly discontinued work on its ENaC inhibitor after reviewing results from phase 1 and phase 1b studies.
Meanwhile, Novartis stopped development of its candidate during a phase 1/2 study due to what the company described as resource-related considerations. Novartis stated that the therapy did not show a meaningful improvement in breathing compared with placebo, although the small study size limited the strength of any conclusions.
Researchers involved in Boehringer’s study pointed to improper dosing and insufficient bronchiolar deposition as possible explanations for the failure of earlier ENaC inhibitor programs. While Boehringer attempted to address those issues, investigators acknowledged that both the dose and duration of treatment may still have been too limited to achieve therapeutic benefit.
Now that the firm has the 28-day data, it plans to organize bigger phase 2b trials in the future.
Cystic Fibrosis treatment research received a major boost after Enterprise announced positive Phase 2 clinical trial results for its investigational therapy. The encouraging data has increased optimism among researchers, healthcare professionals, and investors who are closely monitoring new developments in respiratory disease innovation.
The latest achievement highlights growing momentum in the search for more effective therapies targeting patients living with Cystic Fibrosis worldwide.
Positive Phase 2 Trial Results
Enterprise reported that its Phase 2 study met important clinical endpoints related to safety and treatment effectiveness. The company stated that patients receiving the therapy demonstrated measurable improvements associated with Cystic Fibrosis symptom management and respiratory health.
The successful trial outcome strengthens confidence in the company’s drug development strategy and supports plans for larger late-stage clinical studies.
Future Outlook for Cystic Fibrosis Treatments
Following the successful Phase 2 trial, Enterprise is expected to continue advancing the therapy into larger studies aimed at confirming long-term safety and effectiveness. If future clinical development remains positive, the treatment could become an important addition to the expanding landscape of Enterprise care.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
